Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02852993

Acronym

STeF-BFC

Enrollment

16099

Registered

2016-08-02

Start date

2013-09-30

Completion date

2015-06-30

Last updated

2016-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythrocyte Transfusion for All Conditions

Keywords

Erythrocyte Transfusion, Survival

Brief summary

Red blood cell transfusion (RBC) is the main symptomatic treatment for severe anemia. RBC transfusion has proven its efficacy regarding mortality and morbidity, but it is not without side effects. The infectious side effects of transfusion are largely considered under control, non-infectious side effects are taking center stage. Seeking explanations for the beneficial and deleterious effects of RBC transfusions is necessary to ensure the safe and optimal use of this precious resource. The investigators aim to study the impact of donor and RBC characteristics on patient survival.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Aged 18 and over * Erythrocyte Transfusion between 2007 and 2011 * Performed at the University Hospital of Besançon or Dijon

Exclusion criteria

* Transfusion of any blood product prior to January 1st, 2007

Design outcomes

Primary

Measure	Time frame
Survival	12 months

Countries

France

Outcome results